Ehab Atallah, M.D.
Assistant Professor of Medicine
Ehab Atallah, M.D., is Assistant Professor of Medicine at the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. He also practices medicine in the Department of Hematology/Oncology at the Clement J. Zablocki Veterans Affairs Medical Center. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. He then went on to complete a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas. Dr. Atallah is board certified in Internal Medicine, Medical Oncology, and Hematology. He has authored numerous publications, including journal articles, meeting abstracts, and a book chapter. In 2007, he received the American Society of Clinical Oncology Foundation Merit Award. His current research interests are treatment of patients with newly diagnosed CML, refractory AML and myelodysplastic syndromes.
View our Clinical Trials
1. Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest. 2008;26:208-216.
2. Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2007;5:544-552.
3. Atallah E, Cortes J, O'Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547-3551.
4. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.
5. Atallah E, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol. 2007;14:138-144.
6. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007;8:65-73.